Welcome to our dedicated page for VERADERMICS SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERADERMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERADERMICS's regulatory disclosures and financial reporting.
Veradermics, Inc. Chief Executive Officer and director Reid Alexander Waldman reported insider equity changes. On February 5, 2026, 1,437 shares of Series A Convertible Preferred Stock automatically converted into 1,437 shares of common stock on a 10.067-for-1 basis, bringing his directly held common stock to 234,872 shares.
Separately, on February 3, 2026, he was granted a stock option for 556,399 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.
Veradermics, Incorporated updated its corporate charter and bylaws on February 5, 2026 in connection with the consummation of its initial public offering of common stock. A fifth restated certificate of incorporation became effective upon filing with the Delaware Secretary of State.
The Restated Certificate authorizes 200 million shares of common stock and 25 million shares of undesignated preferred stock, eliminates all prior preferred series, and removes stockholders’ ability to act by written consent. Amended and restated bylaws also took effect, refining stockholder proposal and director nomination procedures, updating director and officer indemnification, and aligning with the new charter provisions.